000			01405 a2200361 4500
005			20250513134832.0
264		0	_c19980408
008			199804s 0 0 eng d
022			_a0340-6997
024	7		_a10.1007/s002590050216 _2doi
040			_aNLM _beng _cNLM
100	1		_aBehr, T M
245	0	0	_aReducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: present status, future prospects and limitations. _h[electronic resource]
260			_bEuropean journal of nuclear medicine _cFeb 1998
300			_a201-12 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review
650	0	4	_aAmino Acids _xadverse effects
650	0	4	_aAnimals
650	0	4	_aAntibodies _xadverse effects
650	0	4	_aClinical Trials as Topic
650	0	4	_aForecasting
650	0	4	_aHumans
650	0	4	_aImmunoglobulin Fab Fragments _xadverse effects
650	0	4	_aKidney _xmetabolism
650	0	4	_aPeptides _xadverse effects
650	0	4	_aRadiation Dosage
650	0	4	_aRadioimmunodetection
650	0	4	_aRadiopharmaceuticals _xadverse effects
700	1		_aGoldenberg, D M
700	1		_aBecker, W
773	0		_tEuropean journal of nuclear medicine _gvol. 25 _gno. 2 _gp. 201-12
856	4	0	_uhttps://doi.org/10.1007/s002590050216 _zAvailable from publisher's website
999			_c9442215 _d9442215